Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,128JPY
23 Apr 2019
Change (% chg)

¥132 (+2.64%)
Prev Close
¥4,996
Open
¥5,100
Day's High
¥5,189
Day's Low
¥5,076
Volume
1,784,300
Avg. Vol
2,045,627
52-wk High
¥5,794
52-wk Low
¥3,277

Select another date:

Fri, Mar 29 2019

Photo

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion (5.2 billion pounds) to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

UPDATE 5-AstraZeneca pays up to $6.9 bln in Daiichi Sankyo cancer deal

* Astra stock slides, deal part-funded by share issue (Releads, adds details on rivalry, analyst comments)

Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps

TOKYO, March 29 Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year.

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

March 28 British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

TOKYO Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

UPDATE 1-Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

TOKYO, March 1 Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

Japan's Daiichi Sankyo exploring sale of OTC business, hires JP Morgan -sources

TOKYO, March 1 Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

BRIEF-Daiichi Sankyo Co, Roche To Collaborate On New HER2 Low Companion Diagnostic Test

* DAIICHI SANKYO AND ROCHE TO COLLABORATE ON NEW HER2 LOW COMPANION DIAGNOSTIC TEST

Select another date: